Valneva Se ADR (VALN) Stock Price, Quote & News

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 2 28 07 37 10

Fax: 33 2 28 07 37 11

Website: valneva.com

Address:

6 rue Alain Bombard, Saint-Herblain, France

Siuolman58 Oct. 7 at 9:09 AM

$VALN Buy on Lyme!!!

0 · Reply

ajmore Oct. 7 at 7:18 AM

$VALN opporrunity to buy, the new guidance hardly differs from previous one and lyme data is due.

1 · Reply

AStrokeOfLuck Oct. 6 at 4:52 PM

$VALN

0 · Reply

NVDAMillionaire Oct. 3 at 9:16 AM

$VALN Excellent article that nails exactly where VALN stands right now. So if you want to update your VALN knowledge or get acquainted with VALN, this is a must read. https://beyondspx.com/quote/VALN/analysis/valneva-s-vaccine-renaissance-lyme-catalyst-and-chikungunya-s-resilient-path-nasdaq-valn

0 · Reply

ajmore Oct. 1 at 11:29 AM

$VALN pfizer's deal with trump, yesterday, gives pfizer 5 years exempt from tarrifs on any product they sell that is manufactured outside the US.

0 · Reply

Riderman29 Oct. 1 at 11:10 AM

$VALN 7% up in Europe, continue strong uptrend

0 · Reply

Papusa Oct. 1 at 8:45 AM

$VALN Production USA or EU for Lyme?

1 · Reply

Papusa Oct. 1 at 8:44 AM

$VALN does anyone know where will be Lyme produced? In EU or USA? In which production plant?

0 · Reply

ajmore Oct. 1 at 7:34 AM

$VALN further thoughts on the 4 year serotype update! commercially: this makes valneva's vaccine first choice. 4 year immunogenicity is cost effective, enhances the herd immunity and lowers risks associated with repetitive vaccinations. Platform: have we got something that can go further, I mean flu vaccines... Large Pharma watching. impressive development.

0 · Reply

topstockalerts Sep. 30 at 12:10 PM

$VALN setting up nicely.. 🍾

0 · Reply

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Sep 30, 2025, 1:00 AM EDT - 7 days ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 3, 2025, 1:00 AM EDT - 4 weeks ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Aug 25, 2025, 12:02 PM EDT - 6 weeks ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Aug 25, 2025, 10:43 AM EDT - 6 weeks ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:29 AM EDT - 6 weeks ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 1:16 AM EDT - 6 weeks ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:00 AM EDT - 6 weeks ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 18, 2025, 1:00 AM EDT - 7 weeks ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 12, 2025, 3:20 PM EDT - 7 weeks ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 1:00 AM EDT - 2 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 7, 2025, 1:18 AM EDT - 2 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Jul 29, 2025, 10:00 AM EDT - 2 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 11, 2025, 11:35 AM EDT - 3 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 8:18 AM EDT - 3 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jun 26, 2025, 1:00 AM EDT - 3 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 25, 2025, 11:45 AM EDT - 3 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 9, 2025, 10:29 AM EDT - 4 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 5, 2025, 11:45 AM EDT - 4 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 4, 2025, 1:00 AM EDT - 4 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

May 26, 2025, 11:30 AM EDT - 4 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

May 12, 2025, 1:00 AM EDT - 5 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 9, 2025, 9:47 AM EDT - 5 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:30 AM EDT - 5 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 7, 2025, 11:45 AM EDT - 5 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 8:40 AM EDT - 5 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 1:00 AM EDT - 5 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 26, 2025, 1:10 PM EDT - 5 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 18, 2025, 4:00 AM EDT - 6 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 16, 2025, 11:45 AM EDT - 6 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 14, 2025, 2:28 PM EDT - 6 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 11:45 AM EDT - 6 months ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 9, 2025, 1:00 AM EDT - 6 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 7, 2025, 9:33 AM EDT - 6 months ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 3, 2025, 11:45 AM EDT - 6 months ago

Valneva SE Shareholding Declaration - March 2025

Apr 1, 2025, 11:45 AM EDT - 6 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Mar 31, 2025, 1:00 AM EDT - 6 months ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 26, 2025, 1:00 PM EDT - 6 months ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 25, 2025, 2:00 AM EDT - 7 months ago

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Mar 24, 2025, 2:00 AM EDT - 7 months ago

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Mar 20, 2025, 8:00 PM EDT - 7 months ago

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 2:00 AM EDT - 7 months ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Mar 19, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Mar 18, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Mar 17, 2025, 10:00 AM EDT - 7 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 16, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation

Siuolman58 Oct. 7 at 9:09 AM

$VALN Buy on Lyme!!!

0 · Reply

ajmore Oct. 7 at 7:18 AM

$VALN opporrunity to buy, the new guidance hardly differs from previous one and lyme data is due.

1 · Reply

AStrokeOfLuck Oct. 6 at 4:52 PM

$VALN

0 · Reply

NVDAMillionaire Oct. 3 at 9:16 AM

0 · Reply

ajmore Oct. 1 at 11:29 AM

$VALN pfizer's deal with trump, yesterday, gives pfizer 5 years exempt from tarrifs on any product they sell that is manufactured outside the US.

0 · Reply

Riderman29 Oct. 1 at 11:10 AM

$VALN 7% up in Europe, continue strong uptrend

0 · Reply

Papusa Oct. 1 at 8:45 AM

$VALN Production USA or EU for Lyme?

1 · Reply

Papusa Oct. 1 at 8:44 AM

$VALN does anyone know where will be Lyme produced? In EU or USA? In which production plant?

0 · Reply

ajmore Oct. 1 at 7:34 AM

0 · Reply

topstockalerts Sep. 30 at 12:10 PM

$VALN setting up nicely.. 🍾

0 · Reply

G101SPM Sep. 30 at 11:12 AM

$VALN $11.80 ask. BUY/NEW LONG POSITION carries SPM 87.06 tag to $25.00 in midterm.

0 · Reply

DaxCo Sep. 30 at 10:41 AM

$VALN 💥↗️ 🔋

0 · Reply

Riderman29 Sep. 30 at 9:26 AM

$VALN today 13% up in Europe and it's not finished 25% in two days

1 · Reply

Riderman29 Sep. 30 at 9:17 AM

$VALN Chickungunya report and Lyme vaccine will go to 30$ directly

0 · Reply

ajmore Sep. 30 at 5:29 AM

$VALN Valneva reports seroresponse four years after single shot of Chickungunya vaccine in IXCHIQ(R). (follow up on 250+ healthy indoviduals that continue to be monitored after trials, across all age groups! THIS IS A BREAKTHOUGH IN TERMS OF VACCINES.

1 · Reply

DaxCo Sep. 29 at 4:24 PM

$VALN any news today? Up 10 %

1 · Reply

Creisi Sep. 27 at 7:05 PM

$VALN Love what this company will be doing in early 2026. The LYME disease vaccine will push this stock to $20-25 a share by April/26, if not earlier

0 · Reply

Jimmity Sep. 26 at 8:36 PM

$VALN Was reading about that kissing bug parasitic infection that is slowly spreading in the U.S.....Seems can be a lot worse than lymne if you don't get the treatment med soon enough.

0 · Reply

ajmore Sep. 26 at 7:21 AM

$VALN In the US Valneva is about the lyme vaccine, Japanese Encp. the first is manufactured in the US (by pfizer) and the second is the only available vaccine and main client is US government. any weakness is oppirtunity for loading up!.

0 · Reply

Creisi Sep. 19 at 4:57 PM

$VALN I think most investors are grossly underestimating the potential of a LYME Disease Vaccine. Tck carrying LYME disease numbers have skyrocketed in the past decade with many high profile celebrities having been infected. The press on this vaccine will greatly elevate its usage and drive sales 2x to 3x hire than projections. VALN will be the winner as I can see the stock hitting $25-30 a share shortly after this Vaccine is launched in the late spring of 2026.

2 · Reply

MaxProfitTrades Sep. 17 at 12:43 PM

$VALN On my watchlist 😎

0 · Reply

topstockalerts Sep. 17 at 12:40 PM

$VALN waking up now..

0 · Reply

Market Cap	978.71M
Revenue (ttm)	183.50M
Net Income (ttm)	-13.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7.22%
Debt to Equity Ratio	0.90

Volume	78,800
Avg Vol	104,464
Day's Range	N/A - N/A
Shares Out	85.93M
Stochastic %K	52%
Beta	1.86
Analysts	Strong Sell
Price Target	$13.28